Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:NBRVNASDAQ:NMRANASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.87-4.3%$3.05$2.30▼$5.54$171.86M-0.17276,172 shs195,097 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs131 shsNMRANeumora Therapeutics$0.84-6.2%$0.74$0.61▼$17.19$136.60M2.731.54 million shs589,778 shsPBYIPuma Biotechnology$3.35-5.9%$3.18$2.23▼$4.13$166.26M1.29444,597 shs318,484 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals0.00%-6.82%-0.69%-21.37%-3.04%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%NMRANeumora Therapeutics0.00%-17.21%+26.84%-34.02%-91.56%PBYIPuma Biotechnology0.00%-9.95%+2.13%+0.90%-6.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.846 of 5 stars3.54.00.00.03.51.70.0NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANMRANeumora Therapeutics1.9436 of 5 stars3.10.00.00.02.22.51.3PBYIPuma Biotechnology4.0878 of 5 stars3.52.00.00.03.03.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50335.54% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ANMRANeumora Therapeutics 2.22Hold$9.29999.55% UpsidePBYIPuma Biotechnology 3.00Buy$7.00108.96% UpsideCurrent Analyst Ratings BreakdownLatest NBRV, ELDN, PBYI, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/2/2025NMRANeumora TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00NMRANeumora TherapeuticsN/AN/AN/AN/A$3.07 per shareN/APBYIPuma Biotechnology$232.71M0.71$0.80 per share4.19$1.12 per share2.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.10N/AN/AN/AN/A-189.99%-28.17%8/18/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ANMRANeumora Therapeutics-$235.93M-$1.61N/AN/AN/AN/A-73.63%-68.97%8/5/2025 (Estimated)PBYIPuma Biotechnology$21.59M$0.776.988.82N/A9.56%41.60%10.71%7/30/2025 (Estimated)Latest NBRV, ELDN, PBYI, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53NBRVNabriva Therapeutics0.120.850.52NMRANeumora TherapeuticsN/A10.9810.98PBYIPuma Biotechnology0.461.421.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%NBRVNabriva Therapeutics0.27%NMRANeumora Therapeutics47.65%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals12.30%NBRVNabriva Therapeutics1.63%NMRANeumora Therapeutics26.80%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableNMRANeumora Therapeutics108161.75 million118.91 millionOptionablePBYIPuma Biotechnology20049.63 million37.45 millionOptionableNBRV, ELDN, PBYI, and NMRA HeadlinesRecent News About These CompaniesShould Value Investors Buy Puma Biotechnology (PBYI) Stock?June 11, 2025 | zacks.comWith 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backingJune 10, 2025 | finance.yahoo.comTwo Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)June 9, 2025 | marketbeat.com78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | businesswire.comMillennium Management LLC Has $5.78 Million Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)May 29, 2025 | marketbeat.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value InvestorsMay 28, 2025 | zacks.comAre Investors Undervaluing Puma Biotechnology (PBYI) Right Now?May 26, 2025 | zacks.comD. E. Shaw & Co. Inc. Buys 165,220 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)May 26, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at Wall Street ZenMay 24, 2025 | marketbeat.comDimensional Fund Advisors LP Has $2.64 Million Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)May 17, 2025 | marketbeat.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable QualityMay 15, 2025 | uk.finance.yahoo.comDespite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain StockMay 12, 2025 | zacks.comPuma Biotech CCO Jeff Ludwig departs, no replacement namedMay 10, 2025 | uk.investing.comPuma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic effortsMay 9, 2025 | msn.comIs Puma Biotechnology (PBYI) Stock Undervalued Right Now?May 9, 2025 | zacks.comPBYI Stock Rises as Q1 Earnings and Sales Beat EstimatesMay 9, 2025 | zacks.comPuma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst ChallengesMay 9, 2025 | gurufocus.comPuma Biotechnology Stock Short Interest Report | NASDAQ:PBYI | BenzingaMay 8, 2025 | benzinga.comPuma Biotech (PBYI) Q1 Earnings and Revenues Top EstimatesMay 8, 2025 | zacks.comPuma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should KnowApril 30, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBRV, ELDN, PBYI, and NMRA Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$2.87 -0.13 (-4.33%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.97 +0.10 (+3.48%) As of 06/13/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Neumora Therapeutics NASDAQ:NMRA$0.84 -0.06 (-6.17%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.85 +0.01 (+0.89%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Puma Biotechnology NASDAQ:PBYI$3.35 -0.21 (-5.90%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.38 +0.03 (+1.01%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
